Description

Bosutinib (CAS: 380843-75-4) is a potent and selective dual inhibitor of Src and Abl tyrosine kinases, with a molecular formula of C₂₆H₂₉Cl₂N₅O₃. This small molecule is widely used in biochemical and pharmaceutical research, particularly in the study of chronic myelogenous leukemia (CML) and other malignancies. Bosutinib, also known by its trade name Bosulif, exhibits high purity (≥98% by HPLC) and is supplied as a fine powder for research applications. Its mechanism of action involves the inhibition of Bcr-Abl kinase, which is crucial for the proliferation of leukemic cells. Researchers rely on Bosutinib for its efficacy in targeting resistant mutations, making it a valuable tool in oncology studies and drug development.

Properties

• CAS Number: 380843-75-4
• Complexity: 734
• IUPAC Name: 4-(2,4-dichloro-5-methoxy-anilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile
• InChI: InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)
• InChI Key: UBPYILGKFZZVDX-UHFFFAOYSA-N
• Exact Mass: 529.1647452
• Molecular Formula: C26H29Cl2N5O3
• Molecular Weight: 530.4
• SMILES: CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC
• Topological: 82.9
• Monoisotopic Mass: 529.1647452
• Synonyms: Bosutinib, 380843-75-4, SKI-606, SKI 606, SKI606, 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile, 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile, SK-606, UNII-5018V4AEZ0, CHEBI:39112, 5018V4AEZ0, EC 700-455-1, SK 606, BOSUTINIB (MART.), BOSUTINIB [MART.], 3-Quinolinecarbonitrile, 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-, 3-QUINOLINECARBONITRILE, 4-((2,4-DICHLORO-5-METHOXYPHENYL)AMINO)-6-METHYL-1-PIPERAZINYL)PROPOXY)-, bosutinibum, L01XE14, 4-Anilinobenzo(g)quinoline-3-carbonitrile, 4-anilino-3-quinolinecarbonitrile, Bosutinib (SKI-606), BOSULIF, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile, Bosutinib (USAN), Bosutinib [USAN], MFCD07367846, 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile, 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile, BOSUTINIB ISOMER 1, CHEMBL288441, 4-(2,4-dichloro-5-methoxyphenylamino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile, SKI-606), Bosutinib [USAN:INN], NCGC00241107-01, Bosutinib (Standard), WAY-173606, Bosutinib,SKI-606, BOSUTINIB [INN], Bosutinib (SKI606), BOSUTINIB [MI], BOSUTINIB [VANDF], PF-5208763, BOSUTINIB [WHO-DD], Bosutinib (SKI-606)?, MLS006011212, SCHEMBL158390, BDBM4552, GTPL5710, Bosutinib Isomer 1, Free Base, Bosutinib, >=98% (HPLC), DTXSID10861568, EX-A391, UBPYILGKFZZVDX-UHFFFAOYSA-N, BCPP000318, HMS2043A22, HMS3244A03, HMS3244A04, HMS3244B03, HMS3651C03, HMS3672K11, HMS3743E09, HMS5079M03, K00615a, BCP01782, HB1323, HY-10158R, NSC765694, NSC799367, AKOS015902521, AC-2413, BCP9000446, CCG-208129, CS-0118, DB06616, FB19002, NSC-765694, NSC-799367, PB30881, SDCCGSBI-0646926.P001, NCGC00241107-03, NCGC00241107-05, 4-(2,4-dichloro-5-methoxy-anilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile, AS-11064, HY-10158, SMR002530350, NS00002757, S1014, SKI606; SKI 606; SK-I606, SW220197-1, D03252, AB01565836_03, EN300-7565041, Q894611, SR-01000941572, SR-01000941572-1, BRD-K99964838-001-01-0, BRD-K99964838-001-06-9, BRD-K99964838-001-11-9, BRD-K99964838-001-12-7, Z2216885221, 4-(2,4-Dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)propoxy]quinoline-3-carbonitrile, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile;SKI 606

Bosutinib is primarily used in research to study its inhibitory effects on Src and Abl tyrosine kinases, particularly in the context of chronic myelogenous leukemia (CML). It is also employed to investigate resistance mechanisms in Bcr-Abl-positive leukemias. Additionally, Bosutinib serves as a reference compound in kinase profiling assays and preclinical studies. Its application extends to the development of targeted therapies for solid tumors and hematologic malignancies.

Safety and Hazards

GHS Hazard Statements

• H317 (41.7%): May cause an allergic skin reaction [Warning Sensitization, Skin]
• H319 (59.7%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]
• H413 (55.6%): May cause long lasting harmful effects to aquatic life [Hazardous to the aquatic environment, long-term hazard]

Precautionary Statements

• P261, P264+P265, P272, P273, P280, P302+P352, P305+P351+P338, P321, P333+P317, P337+P317, P362+P364, and P501

Hazard Classes and Categories

• Skin Sens. 1 (41.7%)
• Eye Irrit. 2 (59.7%)
• Aquatic Chronic 4 (55.6%)

If you are interested or have any questions, please contact us at support@atomfair.com

Disclaimer: Sold exclusively for laboratory research. Prohibited for commercial use, diagnostics, or human/animal applications. Buyers assume all compliance liability.